Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartwatch and nutrition coaching ease cirrhosis symptoms?

NCT ID NCT06136221

Symptom relief Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests a home monitoring program called LiverWatch for people with advanced liver disease (cirrhosis). Participants get a Fitbit, personalized nutrition advice, and weekly check-ins to boost activity and manage symptoms. The goal is to see if this approach improves quality of life compared to standard care alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LiverWatch Intervention (behavioral: nutrition, physical activity, education, and symptom monitoring)
What this could lead to
If it works, this could offer a practical way for people with cirrhosis to manage symptoms and stay healthier at home.
What could go wrong
This is a small, early-stage trial (110 participants) testing a behavioral program, not a drug. Results may not apply to everyone, and benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * English speaking * Aged 18 years or older * Home-dwelling * Diagnosis of cirrhosis- Child Turcotte-Pugh (CTP) B or C or a complication in the past 6 months (CTP B or higher, hepatic encephalopathy, variceal bleeding, fluid overload, liver-related hospitalization, or requiring symptom management with diuretics, non-absorbable disaccharides, rifaximin, nonselective beta blockers) * Patient and/or caregiver is able and willing to receive SMS text messages * Willing and able to wear personal fitness trackers and engage with study staff Exclusion Criteria: * No access to a smartphone * Non-home dwelling * On hospice care * Model for end stage liver disease (MELD) score ≥30 * Advanced hepatocellular carcinoma, BCLC C or higher * Hospitalization within the last 30 days * Deemed not appropriate by treating physician for medical reasons * Enrolled in other dietary or physical activity interventions * Receiving physical therapy as standard of care

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis, liver are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver End Stage Liver Disease muscular atrophy Sedentary Behavior Signs and Symptoms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis, liver End stage liver disease Muscle loss Physical inactivity Symptoms and signs

Contacts and locations

Locations

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.